Supplementary Figure 3 from Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters

Autor: Stephen Safe, Sudhakar Chintharlapalli, Sung-Gook Cho, Yun-Yong Park, Ju-Seog Lee, Un-Ho Jin, Satya S. Pathi, Gayathri Chadalapaka, KyoungHyun Kim

PDF file, 204K, Effects of proteasome and ROS inhibitors.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84228c57c769aec9ddf2cae8e3ec3697
https://doi.org/10.1158/1535-7163.22499247.v1

Supplementary Figure 1 from Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters

Autor: Stephen Safe, Sudhakar Chintharlapalli, Sung-Gook Cho, Yun-Yong Park, Ju-Seog Lee, Un-Ho Jin, Satya S. Pathi, Gayathri Chadalapaka, KyoungHyun Kim

PDF file, 42K, Data mining for ZBTB4 expression.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f566d950e51d809ddaafebfd4a1fad8
https://doi.org/10.1158/1535-7163.22499253

A Cancer-Selective Zinc Ionophore Inspired by the Natural Product Naamidine A

Autor: Rachel M. Vaden, Sasi Arunachalam, Celine B. Santiago, Ryan E. Looper, Justin M. Salvant, Katrin P. Guillen, Bryan E. Welm, Matthew S. Sigman, Satya S. Pathi, Joseph B. Gibbons

Publikováno v: ACS Chem Biol

We present data demonstrating the natural product mimic, zinaamidole A (ZNA), is a modulator of metal ion homeostasis causing cancer-selective cell death by specifically inducing cellular Zn(2+)-uptake in transformed cells. ZNA’s cancer selectivity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::415e9a60b837012fa377775caac7e9e1
https://doi.org/10.1021/acschembio.8b00977

MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer

Autor: Moloy T. Goswami, A. M. Chinnaiyan, Shannon Carskadon, Stephanie Daignault, Sumit Agarwal, Nallasivam Palanisamy, Sooryanarayana Varambally, Balabhadrapatruni V. S. K. Chakravarthi, Marcin Cieślik, Xiaojun Jing, Darshan S. Chandrashekar, L.P. Kunju, Alyncia D. Robinson, Javed Siddiqui, Satya S. Pathi

Publikováno v: Oncogene

MicroRNA-101, a tumor suppressor microRNA (miR), is often downregulated in cancer and is known to target multiple oncogenes. Some of the genes that are negatively regulated by miR-101 expression include histone methyltransferase EZH2 (enhancer of zes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::887b21318d582342bb2ace1e2b2287d0
https://pubmed.ncbi.nlm.nih.gov/27270442

TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer.

Autor: Vaklavas C; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Matsen CB; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Chu Z; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Boucher KM; Department of Internal Medicine, Division of Epidemiology, Salt Lake City, UT., Scherer SD; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Pathi S; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Beck A; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Brownson KE; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Buys SS; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Chittoria N; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., D'Astous E; Huntsman Cancer Institute Clinical Trials Office, Salt Lake City, UT., Gulbahce HE; Department of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Henry NL; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.; Current Address: Department of Internal Medicine, University of Michigan, Ann Arbor, MI., Kimani S; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Porretta J; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Rosenthal R; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Ward J; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Wei M; Department of Internal Medicine, Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Welm BE; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Welm AL; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Jul; Vol. 8, pp. e2300724.